David J. Straus

Hematology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Journal: Future oncology (London, England)
Published: July 06, 2026

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Journal: Advances in therapy
Published: May 08, 2026

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Journal: Blood
Published: July 02, 2025

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Journal: Blood
Published: July 02, 2025

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Journal: Blood advances
Published: February 10, 2025

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Journal: Haematologica
Published: August 01, 2024

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.

Journal: Blood advances
Published: July 17, 2024

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas.

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas.

Journal: Blood neoplasia
Published: February 15, 2024

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

Journal: Blood advances
Published: August 16, 2023

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.

Journal: Haematologica
Published: May 10, 2023

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.

Journal: Blood advances
Published: February 07, 2023

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Journal: Haematologica
Published: February 07, 2023
Showing 1-12 of 92

Last Updated: 09/26/2026